Study of SCI-210 for autism-related behavior in kids
Part of Mental health clinical trials.
This trial tests SCI-210, a cannabis-based medicine, to see if it is safe and can improve challenging behaviors in children and young adults with autism. You may be asked to complete regular check-ins about behavior and development over the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 5 to 18, and you have autism confirmed with official autism testing
- Your child has at least moderate behavior challenges based on a clinician’s rating
- A parent or legal guardian can consent and complete study questionnaires and visits
- You are eligible to receive medical cannabis under Israeli Ministry of Health rules
- Your child is not currently taking cannabis, antipsychotic medicine, or stimulant medicine
- No major medical or mental health conditions that could make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (NV01-A02) in children aged 6 to 15 who have autism. The goal is to see if the drug is safe and helpful for managing autism symptoms.
This trial tests whether a combination of supplements can help children with autism spectrum disorder. It involves taking oral supplements daily for 6 months, along with blood tests and behavior assessments at the start, midpoint, and end.
This trial tests a cannabis oil enriched with terpenes (natural compounds that may affect behavior) to see if it helps reduce severe symptoms in children with autism. It compares the oil to a placebo.
This study tests if a CBD oil enriched with terpenes can help reduce ADHD symptoms in children and teens. It may offer an alternative to standard ADHD medications.
This Phase 2 study tests CBDV, a form of cannabis-based medicine, compared with placebo (dummy medicine) in children with autism who have significant irritability and social challenges. It aims to see whether CBDV can improve behavior and overall symptom severity safely over the study period.
This Phase 1 study tests cannabidiol (CBD) in adults on the autism spectrum who also have mood, sleep, or behavior problems. The goal is to learn whether CBD can be given safely and may help symptoms that affect daily life.
Hear when a new Autism Spectrum Disorder (ASD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.